SCHEMBL1146017

SCHEMBL1146017

CCOc1nc(C(=O)O)cc(N)c1C#N

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 20/20 0.74
MAPK9 P45984 15/20 0.74
MAPK10 P53779 6/20 0.66
RPS27 P42677 4/20 0.66
PRKD2 Q9BZL6 6/20 0.63
PRKD3 O94806 4/20 0.63
MAP4K2 Q12851 2/20 0.63
MAP4K4 O95819 1/20 0.63
PKN2 Q16513 1/20 0.63
STK17A Q9UEE5 1/20 0.63
CSF1R P07333 5/20 0.61
MAPK1 P28482 5/20 0.61
AKT1 P31749 3/20 0.61
CSNK2A1 P68400 1/20 0.61
NTRK2 Q16620 1/20 0.61
PLK3 Q9H4B4 1/20 0.61
ROCK2 O75116 3/20 0.57
CSNK1D P48730 3/20 0.57
DYRK3 O43781 2/20 0.57
RPS6KB1 P23443 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1145329 0.89 MAPK8 (0.74) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL1145277 0.86 MAPK8 (0.75) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514197 0.86 MAPK8 (0.83) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514498 0.85 MAPK8 (0.68) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514223 0.82 MAPK8 (0.76) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514233 0.82 MAPK8 (0.74) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514253 0.81 MAPK8 (0.72) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL13514091 0.80 MAPK8 (0.73) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL1145860 0.80 MAPK8 (1.00) MAPK8MAPK9MAPK10RPS27PRKD2
SCHEMBL1146123 0.80 MAPK8 (0.83) MAPK8MAPK9MAPK10RPS27PRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2375899-B1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES ARRAY BIOPHARMA INC (US) 2015-02-25 EP disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
US-7888374-B2 Inhibitors of c-jun N-terminal kinases ABBOTT LABORATORIES (US) 2011-02-15 US disclosed
US-7888374-B2 Inhibitors of c-jun N-terminal kinases ABBOTT LABORATORIES (US) 2011-02-15 US disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed
WO-2010007756-A1 PYRIDINE DERIVATIVE HAVING TTK INHIBITION ACTIVITY 塩野義製薬株式会社 (JP) 2010-01-21 WO disclosed
WO-2006083673-A2 PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES ABBOTT LABORATORIES (US) 2006-08-10 WO disclosed
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases ABBVIE INC. 2006-08-03 US disclosed
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases ABBVIE INC. 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173050-A1 Inhibitors of c-Jun N-terminal kinases MAPKAPK3, MAP3K3, MAPK3 MAPK8 30/4885MAPK9 49/4885MAPK10 47/4885
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 MAPK8 3189/4885MAPK9 1568/4885MAPK10 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.